Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes

Manabu Itoh, Yosuke Mukae, Takahiro Kitsuka, Kenichi Arai, Anna Nakamura, Kazuyoshi Uchihashi, Shuji Toda, Kumika Matsubayashi, Jun-ichi Oyama, Koichi Node, Daisuke Kami, Satoshi Gojo, Shigeki Morita, Takahiro Nishida, Koichi Nakayama () and Eiji Kobayashi ()
Additional contact information
Manabu Itoh: Saga University
Yosuke Mukae: Saga University
Takahiro Kitsuka: Saga University
Kenichi Arai: Saga University
Anna Nakamura: Saga University
Kazuyoshi Uchihashi: National Hospital Organization Saga Hospital
Shuji Toda: Saga University
Kumika Matsubayashi: Cyfuse Biomedical K. K.
Jun-ichi Oyama: Saga University
Koichi Node: Saga University
Daisuke Kami: Kyoto Prefectural University of Medicine
Satoshi Gojo: Kyoto Prefectural University of Medicine
Shigeki Morita: National Hospital Organization Kyushu Medical Center
Takahiro Nishida: Saga University
Koichi Nakayama: Saga University
Eiji Kobayashi: Keio University School of Medicine

Nature Communications, 2019, vol. 10, issue 1, 1-8

Abstract: Abstract Before they are used in the clinical setting, the effectiveness of artificially produced human-derived tissue-engineered medical products should be verified in an immunodeficient animal model, such as severe combined immunodeficient mice. However, small animal models are not sufficient to evaluate large-sized products for human use. Thus, an immunodeficient large animal model is necessary in order to properly evaluate the clinical efficacy of human-derived tissue-engineered products, such as artificial grafts. Here we report the development of an immunodeficient pig model, the operational immunodeficient pig (OIDP), by surgically removing the thymus and spleen, and creating a controlled immunosuppressive protocol using a combination of drugs commonly used in the clinical setting. We find that this model allows the long-term accommodation of artificial human vascular grafts. The development of the OIDP is an essential step towards a comprehensive and clinically relevant evaluation of human cell regeneration strategies at the preclinical stage.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-10107-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-10107-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-10107-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().